Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462273 | 0.93 | HCRTR1 (0.47) | HCRTR1HCRTR2HSD11B1PTGESPTGS2 | |
| SCHEMBL1462270 | 0.93 | HCRTR1 (0.47) | HCRTR1HCRTR2HSD11B1PTGESPTGS2 | |
| SCHEMBL1462275 | 0.93 | HCRTR1 (0.47) | HCRTR1HCRTR2HSD11B1PTGESPTGS2 | |
| SCHEMBL1558885 | 0.81 | NPSR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL1463374 | 0.80 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL1464086 | 0.80 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL1464089 | 0.80 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL1463401 | 0.77 | PIK3CA (0.45) | HCRTR1HCRTR2MAOBHTR6PIK3CA | |
| SCHEMBL1463240 | 0.77 | NPSR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL1463238 | 0.77 | NPSR1 (0.55) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885MAOB 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.